BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2020 9:16:00 AM | Browse: 698 | Download: 1357
 |
Received |
|
2020-03-16 09:18 |
|
Peer-Review Started |
|
2020-03-16 09:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-26 21:55 |
|
Revised |
|
2020-05-02 09:40 |
|
Second Decision |
|
2020-06-19 10:06 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-06-20 22:55 |
|
Articles in Press |
|
2020-06-20 22:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-06-25 01:54 |
|
Typeset the Manuscript |
|
2020-08-02 12:41 |
|
Publish the Manuscript Online |
|
2020-08-25 09:16 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, Konstantinos Tziomalos and Evangelos Cholongitas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Evangelos Cholongitas, MD, PhD, Associate Professor, First Department of Internal Medicine, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, Agiou Thoma 17, Athens 11527, Greece. cholongitas@yahoo.gr |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Clinical studies; Fatty liver; Animal studies |
| Core Tip |
The strong relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) points to a need to evaluate the therapeutic potential of antidiabetic drugs in patients with NAFLD. Accordingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are well-tolerated antidiabetic agents with no risk of hypoglycemia, seem to be a very appealing therapeutic option for T2DM patients with NAFLD. Herein, based on data from animal studies and clinical trials, we discuss the beneficial impact of GLP-1RAs on NAFLD. |
| Publish Date |
2020-08-25 09:16 |
| Citation |
Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i8/493.htm |
| DOI |
https://dx.doi.org/ 10.4254/wjh.v12.i8.493 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
